Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

BMC Gastroenterology

Research Article

Seungbong Han¹  Sung Won Cho²  Jae Youn Cheong²  Young Min Park³  Kyu Sung Rim⁴  Seong Gyu Hwang⁴  Yun Soo Kim⁵  Ju Hyun Kim⁵  Joo Hyun Sohn⁶  Sang Hoon Park⁷  Choong Kee Park⁸  June Sung Lee⁹  Jeong Won Jang^1,10  Young-Joo Jin^1,11  Jung il Lee^1,11  Jin-Woo Lee^1,12  Hyung Joon Yim^1,13  Chun Kyon Lee^1,14  Sook-Hyang Jeong^1,15  Young Seok Kim^1,16  Jin Mo Yang^1,17 

[1] Department of Biostatistics and Clinical Epidemiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;Department of Internal Medicine, Ajou University School of Medicine, Suwon, South Korea;Department of Internal Medicine, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, South Korea;Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea;Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea;Department of Internal Medicine, Guri Hospital, Hanyang University College of Medicine, Guri, South Korea;Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea;Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea;Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, South Korea;Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Incheon, South Korea;Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea;Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea;Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, 27 Inhang-ro, 400-711, Jung-gu, Incheon, South Korea;Department of Internal Medicine, Korea University College of Medicine, Ansan, South Korea;Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang, Suwon, South Korea;Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea;Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea;Department of Internal Medicine, St.Vincent Hospital, The Catholic University College of Medicine, Suwon, South Korea;

关键词: Chronic hepatitis C;    Pegylated interferon alfa-2a;    Pegylated interferon alfa-2b;    Ribavirin;    Sustained virological response;   

DOI  :  10.1186/1471-230X-13-74

 received in 2012-12-14, accepted in 2013-04-22,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundTwo recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).MethodsThis retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800–1200 mg/day) for 24 or 48 weeks according to HCV genotypes.ResultsEarly virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.ConclusionsUnlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

【 授权许可】

Unknown   
© Jin et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.